New Guidelines for Dopaminergic Therapy Set for Early Parkinson’s
The American Academy of Neurology (AAN) has issued a new group of guidelines designed to aid clinicians in prescribing…
Articles by Patricia Inácio, PhD
Nouryant Again Denied Marketing Approval in Europe
A committee of the European Medicines Agency (EMA) has issued a negative opinion for Nouryant (istradefylline) — approved as Nourianz in…
Lessening Dyskinesia With Duodopa Linked to Better Quality of Life
By lessening the involuntary movements, called dyskinesia, experienced by people with advanced Parkinson’s disease, treatment with AbbVie’s Duodopa…
Bach1 Protein Blocker Seen to Protect Nerve Cells, Ease Symptoms in Mice
A new, potent inhibitor of the Bach1 protein — whose levels are elevated in brain tissue of Parkinson’s disease…
ATH434 Eases Constipation, Other GI Symptoms in Mouse Model
An investigational therapy, ATH434 was able to reverse some gastrointestinal problems in a mouse model of Parkinson’s disease, according to its…
FDA Expands Exablate Neuro’s Use as Motor Symptom Treatment
The U.S. Food and Drug Administration has approved Insightec’s incision-free brain “surgery” technology — Exablate Neuro — for the…
Grants Support Researching Role of Non-neuronal Cell Types
Scientists at the Duke University School of Medicine have received two grants totaling $18 million to investigate how different cells…
Study Assesses How Music Therapy May Improve Fine Motor Skills
A clinical study is assessing whether a specific type of rehabilitation therapy — called neurologic music therapy — may help…
Trial Testing Ketamine as Dyskinesia Treatment Soon Enrolling Patients
A new Phase 2 clinical trial will test the psychedelic painkiller ketamine as a treatment for levodopa-induced dyskinesia in people…
Dosing Begins in Phase 1 Trial of AP-472, for Dyskinesia With Levodopa
A Phase 1 trial of AP-472, Appello Pharmaceutical‘s lead investigational therapy to ease levodopa-induced dyskinesia in Parkinson’s disease, has started…